Drugs for Laryngeal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 345)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ethanol |
Approved |
Phase 4 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
2 |
|
Petrolatum |
Approved, Investigational |
Phase 4 |
|
8009-03-8 |
|
Synonyms:
Multi-hydrocarbon
Paraffinum album
Paraffinum flavum
Petrolatum
Petrolatum base
Petrolatum, white
Petrolatum,amber
|
Petrolatum,white
Petroleum jelly
Soft paraffin
White petrolatum
White, soft paraffin
Yellow soft paraffin
|
|
3 |
|
Mometasone furoate |
Approved, Investigational, Vet_approved |
Phase 4 |
|
83919-23-7 |
4240 441336 |
Synonyms:
(9BETA,10ALPHA,11ALPHA,14BETA,16ALPHA,17ALPHA)-9,21-DICHLORO-11-HYDROXY-16-METHYL-3,20-DIOXOPREGNA-1,4-DIEN-17-YL FURAN-2-CARBOXYLATE
ASMANEX
ASMANEX HFA
ASMANEX TWISTHALER
ELOCON
MOMETASONE
MOMETASONE 17-FUROATE
|
MOMETASONE FUROATE
Mometasone furoate anhydrous
MOMETASONE FUROATE MONOHYDRATE
Mometasone furoic acid
NASONEX
SCH-32088
SINUVA
|
|
4 |
|
Titanium dioxide |
Approved |
Phase 4 |
|
13463-67-7 |
|
Synonyms:
dióxido de titanio
óxido de titanio(4)
|
|
|
5 |
|
Raltitrexed |
Approved, Investigational |
Phase 4 |
|
112887-68-0 |
104758 135400182 |
Synonyms:
Arkomédika brand OF raltitrexed
AstraZeneca brand OF raltitrexed
ICI D1694
ICI-D1694
ICI-D-1694
ICI-D-1694|Tomudex®|ZD1694
N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid
|
Raltitrexed
Tomudex
ZD-16
ZD1694
ZD-1694
Zeneca brand OF raltitrexed
|
|
6 |
|
Mitomycin |
Approved |
Phase 4 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
7 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
8 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
9 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
10 |
|
Dapsone |
Approved, Investigational |
Phase 3 |
|
80-08-0 |
2955 |
Synonyms:
1,1'-Sulfonylbis(4-aminobenzene)
1,1'-Sulfonylbis[4-aminobenzene]
1,1'-Sulphonylbis(4-aminobenzene)
4-(4-Amino-benzenesulfonyl)-phenylamine
4-(4-Amino-benzenesulphonyl)-phenylamine
4-(4-Aminophenylsulfonyl)aniline
4-(4-Aminophenylsulfonyl)benzenamine
4-(4-Aminophenylsulphonyl)aniline
4-(4-Aminophenylsulphonyl)benzenamine
4,4' Diaminophenyl sulfone
4,4'-Dapsone
4,4'-Diaminodiphenyl sulfone
4,4'-Diaminodiphenyl sulphone
4,4'-Diaminodiphenylsulfone
4,4'-Diaminophenyl sulfone
4,4'-Sulfonylbisaniline
4,4'-Sulfonylbisbenzenamine
4,4'-Sulfonylbisbenzeneamine
4,4'-Sulfonyldianilin
4,4'-Sulfonyldianiline
4,4'-Sulphonylbisaniline
4,4'-Sulphonylbisbenzenamine
4-Aminophenyl sulfone
4-Aminophenyl sulphone
Acedapsone
Aczone
Araldite Ht
Avlosulfon
Avlosulfone
Avlosulphone
Bis(4-aminophenyl)sulfone
Bis(4-aminophenyl)sulphone
Bis(p-aminophenyl) sulfone
Bis(p-aminophenyl) sulphone
Croysulfone
Croysulphone
DADPS
Dapsoderm-X
Dapson
Dapsona
DAPSONE
Dapson-fatol
Dapsonum
DDS
Dds, Diaphenylsulfone
DDS, Pharmaceutical
Diaminodifenilsulfona
Diaminodiphenyl Sulfone
Diamino-diphenyl sulphone
Diaminodiphenylsulfone
|
Diaphenylsulfon
DIAPHENYLsulfone
Diaphenylsulphon
DIAPHENYLsulphone
Dimitone
Diphenasone
Diphone
Disulone
DSS
Dubronax
Dumitone
Eporal
Fatol brand OF dapsone
ICI
J04BA02
Metabolite C
Mex-america brand OF dapsone
N, N'-Diphenyl Sulfondiamide
Normet
Novophone
NSC-6091
NSC-6091D
Orsade brand OF dapsone
P, P'-Sulfonyldianiline
p,P'-diaminodiphenyl sulfone
p,P'-diaminodiphenyl sulphone
P,P-Diaminodiphenyl Sulphone
p,p-Sulfonylbisbenzamine
p,p-Sulfonylbisbenzenamine
p,p-Sulphonylbisbenzamine
p,p-Sulphonylbisbenzenamine
P,P-Sulphonyldianiline
p-Aminophenyl sulfone
p-Aminophenyl sulphone
Recolip
Sulfadione
Sulfanona-Mae
Sulfona
Sulfona-Mae
Sulfone Ucb
Sulfone, 4,4'-diaminophenyl
Sulfon-Mere
Sulfonyldianiline
Sulphadione
Sulphon-Mere
Sulphonyldianiline
Sumicure S
Tarimyl
Udolac
|
|
11 |
|
Minocycline |
Approved, Investigational |
Phase 3 |
|
10118-90-8, 13614-98-7 |
54675783 5281021 |
Synonyms:
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
7-Dimethylamino-6-demethyl-6-deoxytetracycline
ACNAMINO
AKNEMIN
AKNEMIN 50
Alti-Minocycline
Apo-Minocycline
ARESTIN
BLEMIX 100
BLEMIX 50
CYCLOMIN
DENTOMYCIN
DYNACIN
Gen-Minocycline
KLINOMYCIN
MINO
Minociclina
Minociclina [INN-Spanish]
Minociclinum
MINOCIN
|
MINOCIN 50
MINOCIN MR
MINOCYCLIN
MINOCYCLINE
MINOCYCLINE HCL
MINOCYCLINE HYDROCHLORIDE
MINOCYCLINUM
Minocyclinum [INN-Latin]
Minocyn
MINOGAL
MINOLIRA
Minomycin
Novo-Minocycline
NSC-141993
SEBOMIN
SEBREN MR
SOLODYN
VECTRIN
XIMINO
|
|
12 |
|
Cobalt |
Approved, Experimental, Withdrawn |
Phase 3 |
|
7440-48-4 |
104729 |
Synonyms:
Aquacat
Co
Co(2+)
Co(II)
CO2+
Cobalt
COBALT (II) ion
Cobalt(2+)
Cobalt(2+) ion
|
Cobalt(II) cation
Cobalt, elemental
Cobalt-59
Cobalto
Cobaltous ion
Cobaltum
Cobatope-57
Kobalt
Super cobalt
|
|
13 |
|
Methotrexate |
Approved |
Phase 3 |
|
1959-05-2, 59-05-2 |
4112 126941 |
Synonyms:
[<sup>3</sup>H]-methotrexate
2-[(4-{[(4-amino-2-imino-2,3-dihydropteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioate
4-Amino-10-methylfolate
4-Amino-10-methylfolic acid
4-Amino-N(10)-methylpteroylglutamate
4-Amino-N(10)-methylpteroylglutamic acid
ABITREXATE
Abitrexate®|amethopterin|Nordimet®|Rasuvo®
Amethopterin
Amethopterine
Antifolan
Arbitrexate
CL-14377
Dicesium salt methotrexate
EBETREX
EMT-25299
Emtexate
EMTEXATE HIGH-POT
EMTEXATE PF
Emtexic acid
FOLEX
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
MAXTREX
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate
Méthotrexate
Methotrexate hydrate
|
Methotrexate sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
METOJECT
Metotrexato
Mexate
MEXATE-AQ
MTX
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
NSC-740
Otrexup
OTREXUP PFS
R-9985
RASUVO
Rheumatrex
R-METHOTREXATE
Sodium, methotrexate
TCMDC-123832
TCMDC-125488
TCMDC-125858
TCMDC-125858TCMDC-125488TCMDC-123832Methotrexate
TCMDC-125858TCMDC-125488TCMDC-123832Methotrexic acid
Trexall
Xatmep
ZLATAL
|
|
14 |
|
Gefitinib |
Approved, Investigational |
Phase 3 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
15 |
|
Sodium citrate |
Approved, Investigational |
Phase 2, Phase 3 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
16 |
|
Palbociclib |
Approved, Investigational |
Phase 3 |
|
571190-30-2 |
5330286 |
Synonyms:
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-D)pyrimidin-7-one
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-{[5-(PIPERAZIN-1-YL)PYRIDIN-2-YL]AMINO}PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
IBRANCE
Ibrance®|PD-0332991|PD0332991
PALBOCICLIB
|
PD 0332991
PD 332991
PD0332991
PD-0332991
UNII-g9Zf61le7g
|
|
17 |
|
Atezolizumab |
Approved, Investigational |
Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
18 |
|
Edetate calcium disodium anhydrous |
Approved, Vet_approved |
Phase 3 |
|
62-33-9, 60-00-4 |
6049 |
Synonyms:
(Ethylenedinitrilo)tetraacetate, ion(4-)
(ethylenedinitrilo)tetraacetic acid, ion(4−)
(Ethylenedinitrilo)tetraacetic acid, ion(4-)
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetate
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetIC ACID
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid
Acid, edetic
Acid, ethylenediaminetetraacetic
Acid, ethylenedinitrilotetraacetic
Acide edetique
Acide ethylenediaminetetracetique
Acido edetico
Acidum edeticum
CaEDTA
Calcioedetato de sodio
Calcitetracemate, disodium
Calcium disodium edetate
Calcium disodium edetic acid
Calcium disodium edta
Calcium disodium ethylenediamine tetraacetate
Calcium disodium ethylenediamine tetraacetic acid
Calcium disodium ethylenediaminetetraacetate
Calcium disodium ethylenediaminetetraacetic acid
Calcium disodium versenate
Calcium disodium versenic acid
Calcium edetate de sodium
CALCIUM EDETATE SODIUM
Calcium edetic acid de sodium
Calcium edta
Calcium sodium 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate (1/2/1)
Calcium sodium 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid (1/2/1)
CALCIUM SODIUM EDETATE HYDRATE
Calcium sodium edta
Calcium tetacine
CaNa2Edta
Chelaton 3
Chromium edta
Copper edta
Coprin
Dicobalt edta
Dinitrilotetraacetate, disodium ethylene
Dinitrilotetraacetate, ethylene
Disodium calcitetracemate
Disodium calcium edta
Disodium calcium ethylenediaminetetraacetate
Disodium calcium ethylenediaminetetraacetic acid
Disodium edta
Disodium ethylene dinitrilotetraacetate
Disodium monocalcium edta
Disodium versenate, calcium
Distannous edta
E385
Edathamil
Edetate
Edetate calcium
Edetate calcium disodium
Edetate calcium disodium (anhydrous)
Edetate disodium calcium
Edetate, calcium disodium
Edetates
|
Edetic acid
Edetic acid calcium disodium
Edetic acid calcium disodium (anhydrous)
Edetic acid calcium disodium salt
Edetic acid, calcium salt
Edetic acid, calcium, sodium salt
Edetic acid, chromium salt
Edetic acid, dipotassium salt
Edetic acid, disodium salt
Edetic acid, disodium salt, dihydrate
Edetic acid, disodium, magnesium salt
Edetic acid, disodium, monopotassium salt
Edetic acid, magnesium salt
Edetic acid, monopotassium salt
Edetic acid, monosodium salt
Edetic acid, potassium salt
Edetic acid, sodium salt
EDT
EDTA
EDTA CALCIUM DISODIUM
EDTA calcium disodium salt
EDTA disodium calcium salt
EDTA, calcium derivative, disodium salt
EDTA, chromium
EDTA, copper
EDTA, dicobalt
EDTA, disodium
EDTA, distannous
EDTA, gallium
EDTA, ion(4-)
EDTA, magnesium disodium
EDTA, potassium
EDTA, stannous
EDTHAMIL
Ethylene dinitrilotetraacetate
Ethylene dinitrilotetraacetate, disodium
Ethylenediaminetetraacetate
Ethylenediaminetetraacetate calcium disodium salt
Ethylenediaminetetraacetic acid
Ethylenediaminetetraacetic acid calcium disodium salt
Ethylenedinitrilotetraacetic acid
Gallium edta
H4EDta
Magnesium disodium edta
Monocalcium disodium edta
N,N'-1,2-ethane diylbis-(N-(carboxymethyl)glycine)
N,N'-1,2-ethanediylbis(N-(carboxymethyl)glycine)
Natrii calcii edetas
Potassium edta
Sodium calcium edetate
Sodium calcium edetic acid
SODIUM CALCIUMEDETATE
Stannous edta
Tetacine, calcium
Tetracemate
Versenate
Versenate, calcium disodium
Versene
Versene acid
VERSENE CA
|
|
19 |
|
Pentetic acid |
Approved |
Phase 3 |
|
67-43-6 |
|
Synonyms:
[[(Carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetate]
[[(Carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetic acid]
1,1,4,7,7-Diethylenetriaminepentaacetate
1,1,4,7,7-Diethylenetriaminepentaacetic acid
Ca-dtpa
CaDTPA
Calcium trisodium pentetate
CaNa-dtpa
Complexon V
DETAPAC
Diethylene triamine pentaacetic acid
Diethylenetriamine pentaacetic acid
Diethylenetriamine-N,N,n',n'',n''-pentaacetate
Diethylenetriamine-N,N,n',n'',n''-pentaacetic acid
Diethylenetriaminepentaacetate
Diethylenetriaminepentaacetic acid
Diethylenetriaminepentacetate
Diethylenetriaminepentacetic acid
DTPA
DTP-A
H5dTpa
Indium dtpa
|
Indium-dtpa
MN-Dtpa
N,N,N',n'',n''-diethylenetriaminepentaacetate
N,N,N',n'',n''-diethylenetriaminepentaacetic acid
N,N-Bis[2-[bis(carboxymethyl)amino]ethyl]glycine
NSC-7340
Pentaacetic acid, diethylenetriamine
Pentacarboxymethyldiethylenetriamine
Pentacin
Pentacine
Pentaind
Pentetate
Pentetate calcium trisodium
Pentetate zinc trisodium
Pentetate, calcium trisodium
Pentetates
PENTETIC ACID
Penthanil
sn-DTPA
Titriplex V
Zinc dtpa
Zinc-dtpa
|
|
20 |
|
Melatonin |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
73-31-4 |
896 |
Synonyms:
[<sup>3</sup>H]-melatonin|[<sup>3</sup>H]MLT
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} acetamide
3-(2-Acetamidoethyl)-5-methoxyindole
5-Methoxy-N-acetyltryptamine
BCI-049
Circadin
Circadin®|MLT
GENERAL NUTRIT
HEALTH AID
HEIDADOUPPI
ICENIA
J5.258B
LIFE EXT
MELAPURE
Melatol
Melatonin
Melatonin (synth.) standard-grade
Melatonin (synth.) ultra-pure
Melatonina
Melatonine
Mélatonine
Melovine
MLT
|
MT6
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-acetamide
N-Acetyl-5-methoxytryptamine
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine melatonine
NATROL
NATURE'S BLEND
NATURES BOUNTY
NSC-113928
NSC-56423
QUALITY HEALTH
Regulin
S.GARD
TRAVELAG
VESPRO
VYTALONIN
|
|
21 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 2, Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
22 |
|
Kava |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
9000-38-8 |
|
23 |
|
Zalutumumab |
Investigational |
Phase 3 |
|
667901-13-5 |
|
Synonyms:
2F8
HUMAX-EGFR
HUMAX-EGFR, 2F8
|
HUMAX-EGFR-2F8
ZALUTUMUMAB
|
|
24 |
|
Tirapazamine |
Investigational |
Phase 3 |
|
27314-97-2 |
135413511 |
Synonyms:
1,2,4-benzotriazin-3-amine, 1,4-dioxide
3-Amino-1,2,4-benzotriazine 1,4-dioxide
SR259075
|
SR-259075
Tirapazamine
WIN-59075
|
|
25 |
|
Nimorazole |
Investigational |
Phase 3 |
|
6506-37-2 |
23009 |
Synonyms:
Esclama
Naxogin
Nimorazole
|
Nitrimidazine
Nulogyl
Pharmacia brand OF nimorazole
|
|
26 |
|
Endostatins |
|
Phase 3 |
|
|
|
27 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
28 |
|
1,2-diaminocyclohexaneplatinum II citrate |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Citrate |
|
Phase 2, Phase 3 |
|
|
|
30 |
|
Lugol's solution |
|
Phase 3 |
|
|
|
31 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
32 |
|
Chelating Agents |
|
Phase 3 |
|
|
|
33 |
|
Antiprotozoal Agents |
|
Phase 3 |
|
|
|
34 |
|
Antiparasitic Agents |
|
Phase 3 |
|
|
|
35 |
|
Radiopharmaceuticals |
|
Phase 3 |
|
|
|
36 |
|
Anticoagulants |
|
Phase 3 |
|
|
|
37 |
|
Blood Substitutes |
|
Phase 3 |
|
|
|
38 |
|
Plasma Substitutes |
|
Phase 3 |
|
|
|
39 |
|
Technetium Tc 99m Pentetate |
|
Phase 3 |
|
|
|
40 |
|
Dextrans |
|
Phase 3 |
|
|
|
41 |
|
Orange |
Approved |
Phase 2 |
|
|
|
42 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
43 |
|
Axitinib |
Approved, Investigational |
Phase 2 |
|
319460-85-0 |
6450551 |
Synonyms:
AG 013736
AG 013736|AG-013736|AG013736|Inlyta®
AG013736
AG-013736
AG-13736
|
AXITINIB
AXITINIBUM
INLYTA
N-METHYL-2-({3-[(E)-2-(PYRIDIN-2-YL)VINYL]-1H-INDAZOL-6-YL}SULFANYL)BENZAMIDE
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
|
|
44 |
|
Irinotecan |
Approved, Investigational |
Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
45 |
|
Nintedanib |
Approved |
Phase 2 |
|
656247-17-5 |
135423438 9809715 |
Synonyms:
BIBF 1120
BIBF1120
BIBF-1120
BIBF-1120|BIBF1120|Ofev®|Vargatef®
INTEDANIB
|
METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
NINTEDANIB
Nintedanib esylate
Ofev
Vargatef
|
|
46 |
|
Metformin |
Approved |
Phase 1, Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
47 |
|
Acetylcysteine |
Approved, Investigational |
Phase 2 |
|
616-91-1 |
581 12035 |
Synonyms:
(2R)-2-ACETAMIDO-3-SULFANYLPROPANOIC ACID
(2R)-2-Acetylamino-3-sulfanylpropanoate
(2R)-2-Acetylamino-3-sulfanylpropanoic acid
(2R)-2-Acetylamino-3-sulphanylpropanoate
(2R)-2-Acetylamino-3-sulphanylpropanoic acid
(R)-2-Acetylamino-3-mercaptopropanoate
(R)-2-Acetylamino-3-mercaptopropanoic acid
(R)-Mercaptate
(R)-Mercaptic acid
(R)-Mercapturic acid
2-[(1-Hydroxyethylidene)amino]-3-sulfanylpropanoate
2-[(1-Hydroxyethylidene)amino]-3-sulphanylpropanoate
2-[(1-Hydroxyethylidene)amino]-3-sulphanylpropanoic acid
2-acetylamino-3-mercapto-Propionate
2-acetylamino-3-mercapto-Propionic acid
5052
Ac pharma brand OF acetylcysteine
ACC
ACC-600
Acebraus
Acemuc
Acetabs
Acetadote
Acetilcisteina
Acetylcystein al
Acetylcystein atid
Acetylcystein heumann
Acetylcystein trom
Acetylcystein, mentopin
Acetylcysteine
Acetylcysteine ac-pharma brand
Acetylcysteine alcon brand
Acetylcysteine aluid brand
Acetylcysteine atid brand
Acetylcysteine azupharma brand
Acetylcysteine betapharm brand
Acetylcysteine bioiberica brand
Acetylcysteine bouchara brand
Acetylcysteine centrafarm brand
Acetylcysteine disphar brand
Acetylcysteine farmasan brand
Acetylcysteine fresenius brand
Acetylcysteine génévrier brand
Acétylcystéine GNR
Acetylcysteine GNR-pharma brand
Acetylcysteine guerbet brand
Acetylcysteine hermes brand
Acetylcysteine heumann brand
Acetylcysteine hydrochloride
Acetylcysteine inpharzam brand
Acetylcysteine intra brand
Acetylcysteine klinge brand
Acetylcysteine krewel brand
Acetylcysteine lichtenstein brand
Acetylcysteine lindopharm brand
Acetylcysteine merck brand
Acetylcysteine oberlin brand
Acetylcysteine pfleger brand
Acetylcysteine pharbita brand
Acetylcysteine roberts brand
Acetylcysteine sodium
Acetylcysteine temmler brand
Acetylcysteine teva brand
Acetylcysteine thiemann brand
Acetylcysteine trommsdorff brand
Acetylcysteine upsa brand
Acetylcysteine whitehall brand
Acetylcysteine zambon brand
Acetylcysteine zinc
Acetylcysteine zyma brand
Acetylcysteine, (D)-isomer
Acetylcysteine, (DL)-isomer
Acetylcysteine, monoammonium salt
Acetylcysteine, monosodium salt
Acetylcysteinum
Acetylin
Acetyst
Acid, mercapturic
Ac-pharma brand OF acetylcysteine
A-CYS
Airbron
Alcon brand OF acetylcysteine
Allen and hanburys brand OF acetylcysteine
Aluid brand OF acetylcysteine
Alveolex
Atid brand OF acetylcysteine
Azubronchin
Azupharma brand OF acetylcysteine
Betapharm brand OF acetylcysteine
Bioiberica brand OF acetylcysteine
Bisolvon nac
Boehringer ingelheim brand OF acetylcysteine
Bouchara brand OF acetylcysteine
Bristol myers squibb brand OF acetylcysteine
Bristol myers squibb brand OF acetylcysteine sodium salt
Bristol-myers squibb brand OF acetylcysteine
Bristol-myers squibb brand OF acetylcysteine sodium salt
Bromuc
broncho Fips
broncho-Fips
BronchoFips
Broncholysin
Broncoclar
Centrafarm brand OF acetylcysteine
CETYLEV
Codotussyl
Cystamucil
dampo Mucopect
|
Dey brand OF acetylcysteine sodium salt
Disphar brand OF acetylcysteine
Durabronchal
EN-CYS
Eurespiran
Exomuc
Fabrol
Farmasan brand OF acetylcysteine
Fluimicil infantil
Fluimucetin
Fluimucil
FLUIMUCIL 600
FLUIMUCIL LONG
FLUIMUCIL N
Flumucetin
Fluprowit
Frekatuss
Fresenius brand OF acetylcysteine
Genac
Génévrier brand OF acetylcysteine
GNR Pharma brand OF acetylcysteine
GNR-Pharma brand OF acetylcysteine
Guerbet brand OF acetylcysteine
Hermes brand OF acetylcysteine
Heumann brand OF acetylcysteine
Hoestil
Hustengetränk, optipect
Hydrochloride, acetylcysteine
Ilube
Inpharzam brand OF acetylcysteine
Intra brand OF acetylcysteine
Jenacystein
Jenapharm
Klinge brand OF acetylcysteine
Krewel brand OF acetylcysteine
L-a-Acetamido-b-mercaptopropionate
L-a-Acetamido-b-mercaptopropionic acid
L-Acetylcysteine
L-alpha-Acetamido-beta-mercaptopropionate
L-alpha-Acetamido-beta-mercaptopropionic acid
Lantamed
Larylin nac
Lichtenstein brand OF acetylcysteine
Lindocetyl
Lindopharm brand OF acetylcysteine
Lysox
L-Α-acetamido-β-mercaptopropionate
L-Α-acetamido-β-mercaptopropionic acid
m Pectil
Mentopin acetylcystein
Mercaptate
Mercaptic acid
Mercapturic acid
Merck brand OF acetylcysteine
Monoammonium salt acetylcysteine
Monosodium salt acetylcysteine
m-Pectil
MPectil
Muciteran
muco Sanigen
Mucolysin
Mucomyst
Mucopect, dampo
Mucosil
MUCOSIL-10
MUCOSIL-20
Mucosol
Mucosolvin
N Acetyl L cysteine
N Acetylcysteine
NAC
NAC al
NAC zambon
NAC, bisolvon
N-Acetyl-3-mercaptoalanine
N-Acetylcysteine
N-Acety-L-cysteine
N-Acetyl-L-(+)-cysteine
N-Acetyl-L-cysteine
NSC-111180
Oberlin brand OF acetylcysteine
Optipect hustengetränk
ORONAC 600
PARVOLEX
Pfleger brand OF acetylcysteine
Pharbita brand OF acetylcysteine
Produpharm lappe brand OF acetylcysteine
RESPI-NAC
Roberts brand OF acetylcysteine
Roche nicholas brand OF acetylcysteine
Sanigen, muco
Siccoral
Siran
Sodium 2-acetamido-3-mercaptopropionate
Sodium, acetylcysteine
Solmucol
Temmler brand OF acetylcysteine
Teva brand OF acetylcysteine
Thiemann brand OF acetylcysteine
Trommsdorff brand OF acetylcysteine
UPSA brand OF acetylcysteine
Whitehall brand OF acetylcysteine
YOURNAC
Zambon brand OF acetylcysteine
Zambon, nac
Zinc, acetylcysteine
Zyma brand OF acetylcysteine
|
|
48 |
|
Romidepsin |
Approved, Investigational |
Phase 2 |
|
128517-07-7 |
5352062 |
Synonyms:
ANTIBIOTIC FR 901228
CHROMADAX
DEPSIPEPTIDE
FK228
FK-228
FK228|FR901228|Istodax®
FR901228
|
FR-901228
ISTODAX
NSC-630176
ROMIDEPSIN
Romidepsina
Romidepsine
Romidepsinum
|
|
49 |
|
Bortezomib |
Approved, Investigational |
Phase 2 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
50 |
|
Acalabrutinib |
Approved, Investigational |
Phase 2 |
|
1420477-60-6 |
71226663 71226662 |
Synonyms:
ACALABRUTINIB
Acalabrutinibum
ACP-196
|
ACP-196|Calquence®|Example 6 [US20140155385 A1]
CALQUENCE
EXAMPLE 6 [US20140155385 A1]
|
|
Interventional clinical trials:
(show top 50)
(show all 1129)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Prospective Randomized Controlled Clinical Study of Albumin-bound Paclitaxel Combined With Cisplatin (AP Regimen) Versus Docetaxel Combined With Cisplatin (TP Regimen) Induced Chemotherapy in Advanced Head and Neck Squamous Tummor |
Unknown status |
NCT04766827 |
Phase 4 |
albumin-bound paclitaxel |
2 |
Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy |
Unknown status |
NCT02495064 |
Phase 4 |
Mometasone Furoate Cream |
3 |
Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer |
Completed |
NCT03998696 |
Phase 4 |
Cisplatin 40 mg/m2;Cisplatin 100 mg/m2 |
4 |
Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors |
Completed |
NCT01344356 |
Phase 4 |
|
5 |
Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial |
Recruiting |
NCT03196843 |
Phase 4 |
Raltitrexed |
6 |
A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10). |
Active, not recruiting |
NCT04489888 |
Phase 4 |
Pembrolizumab;Carboplatin;Paclitaxel |
7 |
Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck |
Terminated |
NCT02015650 |
Phase 4 |
Cetuximab;Mitomycin-C/ 5-Fluorouracil |
8 |
Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx |
Withdrawn |
NCT03388931 |
Phase 4 |
|
9 |
SCT-I10A Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase III, Multicenter, Randomized, Double-blinded Trial |
Unknown status |
NCT04146402 |
Phase 3 |
SCT-I10A+chemo;Placebos+chemo |
10 |
Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma |
Unknown status |
NCT01874171 |
Phase 3 |
Cisplatin;Cetuximab |
11 |
Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy(Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ) Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(R/M SCCHN) |
Unknown status |
NCT03855384 |
Phase 3 |
TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU);placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU) |
12 |
A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region |
Unknown status |
NCT02630264 |
Phase 3 |
Endostatins;Paclitaxel injection;Cisplatin injection |
13 |
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin |
Unknown status |
NCT00999700 |
Phase 3 |
docetaxel - cisplatin - 5-fluorouracil;cetuximab;cisplatin |
14 |
Postoperative Radiation and Concurrent Chemotherapy With Weekly Docetaxel Versus Cisplatin in Patients With High Risk Squamous Cell Carcinoma of Head & Neck: a Randomized Multi-center Phase III Clinical Trial |
Unknown status |
NCT02923258 |
Phase 2, Phase 3 |
Docetaxel;Cisplatinum |
15 |
A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT |
Completed |
NCT01931150 |
Phase 3 |
Topical Dapsone 5% Gel;oral antibiotics |
16 |
A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients |
Completed |
NCT02551159 |
Phase 3 |
5-fluorouracil (5FU);Cisplatin;Carboplatin |
17 |
Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma |
Completed |
NCT01864850 |
Phase 3 |
|
18 |
Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC) |
Completed |
NCT04137627 |
Phase 3 |
Melatonin 20 MG Oral Capsule;Placebo oral capsule |
19 |
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Completed |
NCT02741570 |
Phase 3 |
Cetuximab/Erbitux;Cisplatin/Platinol;Carboplatin/Paraplatin;Fluorouracil/Adrucil |
20 |
Relationship Between Changes in Body Composition and Supplementation With EPA in Patients Diagnosed With Squamous Cell Carcinoma of Head and Neck Locally Advanced (Stage III-IVb) |
Completed |
NCT02715596 |
Phase 3 |
|
21 |
Phase III Randomized Comparison of Radiotherapy Fractionation in Advanced Squamous Cell Carcinoma of the Head and Neck: Twice-Daily Hyperfractionation vs Split-Course Accelerated Hyperfractionation vs Accelerated Fractionation With Concomitant Boost vs Standard Fractionation |
Completed |
NCT00771641 |
Phase 3 |
|
22 |
An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Completed |
NCT02105636 |
Phase 3 |
Nivolumab;Cetuximab;Methotrexate;Docetaxel |
23 |
A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) |
Completed |
NCT01950689 |
Phase 3 |
Nimorazole |
24 |
Phase I/II Trial of Erlotinib, Radiation Therapy, and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck |
Completed |
NCT00442455 |
Phase 3 |
Erlotinib chlorhydrate;Cisplatin |
25 |
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Completed |
NCT03349710 |
Phase 3 |
Cetuximab;Cisplatin |
26 |
DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck |
Completed |
NCT00496652 |
Phase 3 |
Zalutumumab |
27 |
Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma |
Completed |
NCT00158652 |
Phase 3 |
5FU, Paraplatin |
28 |
Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Completed |
NCT00122460 |
Phase 3 |
Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU);Platinum (Cisplatin or Carboplatin) + 5-FU |
29 |
Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomized Phase III Factorial Study. |
Completed |
NCT01086826 |
Phase 3 |
RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB) |
30 |
A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma |
Completed |
NCT00162708 |
Phase 2, Phase 3 |
CDDP, 5 Fu |
31 |
Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer |
Completed |
NCT00174837 |
Phase 3 |
Tirapazamine;Cisplatin |
32 |
Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety of Cetuximab When Given in Combination With Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects |
Completed |
NCT01012258 |
Phase 3 |
|
33 |
A Multicenter, Randomized, Open-label, Phase III Trial to Assess Efficacy and Safety of Cetuximab When Given in Combination With Cisplatin Plus 5 Fluorouracil Versus Cisplatin Plus 5-fluorouracil Alone for the First-line Treatment of Chinese Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Completed |
NCT02383966 |
Phase 3 |
Cetuximab;Cisplatin/Carboplatin;5-fluorouracil |
34 |
Phase III Placebo-Controlled Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Patients |
Completed |
NCT00201279 |
Phase 3 |
13-cis Retino Acid |
35 |
A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck |
Completed |
NCT00206219 |
Phase 3 |
Gefitinib;methotrexate |
36 |
Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients |
Completed |
NCT00201383 |
Phase 3 |
cisplatin |
37 |
An Open-label, Randomized, Parallel-group, Multicenter Study of Neoadjuvant Docetaxel(Taxotere®) Plus Cisplatin Plus 5-fluorouracil Versus Neoadjuvant Cisplatin Plus 5-fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck |
Completed |
NCT00995293 |
Phase 3 |
DOCETAXEL;CISPLATIN;5-FLUOROURACIL |
38 |
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Completed |
NCT02369874 |
Phase 3 |
MEDI4736;MEDI4736 + Tremelimumab;Standard of Care |
39 |
Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy |
Completed |
NCT02347332 |
Phase 3 |
Vinflunine;Methotrexate |
40 |
Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux |
Completed |
NCT00609284 |
Phase 3 |
cetuximab;Carboplatin, 5FU concomitant |
41 |
Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma |
Completed |
NCT01542931 |
Phase 2, Phase 3 |
TPF induction chemotherapy |
42 |
A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02 |
Completed |
NCT01427478 |
Phase 3 |
AFATINIB;Placebo of AFATINIB |
43 |
Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety Profile of Cetuximab When Given in Combination With Chemotherapy for the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck in Asian Subjects |
Completed |
NCT01177956 |
Phase 3 |
Cisplatin;5-Fluorouracil |
44 |
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck |
Recruiting |
NCT01810913 |
Phase 2, Phase 3 |
Atezolizumab;Cisplatin;Docetaxel |
45 |
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers |
Recruiting |
NCT05063552 |
Phase 2, Phase 3 |
Carboplatin;Cisplatin;Docetaxel |
46 |
Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Recruiting |
NCT05050162 |
Phase 2, Phase 3 |
Cisplatin |
47 |
A Phase 3, Randomized, Open-label Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma |
Recruiting |
NCT03815903 |
Phase 3 |
Induction chemotherapy |
48 |
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer |
Recruiting |
NCT04333537 |
Phase 2, Phase 3 |
Imaging Agent |
49 |
A Phase 3, Prospective,Multicenter, Randomized Open-Label Trial to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Chemotherapy Followed By Surgery Versus Up-Front Surgery as Treatment for Resectable Head And Neck Squamous Cell Carcinoma |
Recruiting |
NCT05582265 |
Phase 3 |
Tislelizumab(neoadjuvant);Cisplatin (neoadjuvant);Nab-paclitaxel (neoadjuvant);Cisplatin(adjuvant);Tislelizumab(adjuvant) |
50 |
Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck |
Recruiting |
NCT01893307 |
Phase 2, Phase 3 |
|
|